EP1009379A1 - Use of a substance agonist of a receptor associated with a chlorine or potassium canal for treating sensitive skins - Google Patents

Use of a substance agonist of a receptor associated with a chlorine or potassium canal for treating sensitive skins

Info

Publication number
EP1009379A1
EP1009379A1 EP98942793A EP98942793A EP1009379A1 EP 1009379 A1 EP1009379 A1 EP 1009379A1 EP 98942793 A EP98942793 A EP 98942793A EP 98942793 A EP98942793 A EP 98942793A EP 1009379 A1 EP1009379 A1 EP 1009379A1
Authority
EP
European Patent Office
Prior art keywords
chlorine
composition
skin
cosmetic
receptor associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98942793A
Other languages
German (de)
French (fr)
Inventor
Lionel Breton
Olivier De Lacharriere
Isabelle Nonotte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOreal SA filed Critical LOreal SA
Publication of EP1009379A1 publication Critical patent/EP1009379A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin

Definitions

  • the present invention relates to the use of an agonist substance of a receptor associated with a chlorine channel or with a potassium channel, with the exception of amino acids and their derivatives, in a cosmetic and / or dermatological composition, to treat sensitive skin, including the scalp, and mucous membranes, of humans. It also relates to a method of treating sensitive skin.
  • the Applicant has carried out numerous clinical tests and has been able to determine the symptoms associated with sensitive skin. These symptoms are in particular subjective signs, which are essentially dysaesthetic sensations. By dysesthetic sensations is meant more or less painful sensations felt in a skin area such as tingling, tingling, itching or itching, burning, heating, discomfort, tightness, etc.
  • the Applicant has in particular been able to show that sensitive skin is not allergic skin. (See for this purpose patent FR-A-2,719,474). The Applicant has thus found that sensitive skin can be divided into two main clinical forms, irritable and / or reactive skin, and intolerant skin.
  • Irritable and / or reactive skin is skin that reacts with pruritus, that is to say, by itching, or by tingling, to various factors such as the environment, emotions, food, wind, friction, razor, soap, surfactants, hard water with a high concentration of lime, temperature variations or wool.
  • these signs are associated with dry skin with or without sores, or with skin that has an erythema.
  • Intolerant skin is skin that reacts with feelings of heating, tightness, tingling and / or redness, to various factors such as the environment, emotions, food.
  • these signs are associated with hyperseborrheic or acne-prone skin with or without sores, and erythema.
  • “Sensitive” scalps have a more unequivocal clinical semiology: the sensations of pruritus and / or tingling and / or overheating are essentially triggered by local factors such as friction, soap, surfactants, hard water with a high concentration of limestone. , shampoos or lotions. These sensations are also sometimes triggered by factors such as the environment, emotions and / or food. Erythema and hyperseborrhea of the scalp and dandruff are frequently associated with the above signs.
  • the Applicant has now discovered that sensitive skin is linked to a change in the nervous excitability of the skin. Therefore, the use receptor agonists associated with the chlorine and / or potassium channels present in the skin tissue can make it possible to obtain a preventive and / or curative effect for sensitive skin.
  • the cell membranes of each nerve fiber include numerous ion channels, and in particular chlorine or potassium channels.
  • the role of these different channels is to allow the chlorides and potassium ions, a passage on both sides of the nervous cell membrane, these ionic exchanges (negatively charged chloride inlets and positively charged potassium exits) lead to electrical modifications. which make sensitive nerve fibers less excitable (this phenomenon is called membrane hyperpolarization).
  • the neural receptors associated with the chlorine or potassium channels are in particular for the chlorine channels receptors for glycine (sensitive glycine-strychnine receptors) and receptors for GABA (GABAA receptors).
  • the skin tissue contains receptors associated with the chlorine or potassium channels, which, until now, had not been envisaged and that there was a link between the chlorine or potassium channels of the sensitive nerve fibers of the peripheral nervous system of the skin and sensitive skin. She therefore found that we could act on these channels to treat sensitive skin.
  • the present invention relates to the use of at least one agonist substance of at least one receptor associated with at least one chlorine or potassium channel, present in the skin tissue, with the exception of amino acids and their derivatives, in and / or for the manufacture of a topical cosmetic or dermatological composition for treating sensitive skin.
  • the invention also relates to the use of at least one agonist substance of at least one receptor associated with at least one chlorine or potassium channel, present in the skin tissue, with the exception of amino acids and their derivatives. , in and / or for the manufacture of a topical cosmetic or dermatological composition for treating, or even eliminating, itching, pruritus, tingling, heating, tightness, tingling and / or erythema.
  • the invention also relates to the use of at least one agonist substance of at least one receptor associated with at least one chlorine or potassium channel of at least one cutaneous nerve afference, with the exception of amino acids and their derivatives, in and / or for the manufacture of a topical cosmetic or dermatological composition for treating sensitive skin.
  • the invention also relates to the use of at least one agonist substance of at least one receptor associated with at least one chlorine or potassium channel of at least one cutaneous nerve afference, with the exception of amino acids and their derivatives, in and / or for the manufacture of a topical cosmetic and / or dermatological composition for treating, or even eliminating, itching, pruritus, tingling, overheating, tightness, tingling and / or erythema.
  • the subject of the invention is also a method of cosmetic treatment of sensitive skin, consisting in applying topically to the skin of a subject with sensitive skin, a cosmetic topical composition, containing at least one agonist substance of at least one receptor associated with at least one chlorine or potassium channel present in the skin tissue, with the exception of amino acids and their derivatives ,.
  • a cosmetic topical composition containing at least one agonist substance of at least one receptor associated with at least one chlorine or potassium channel present in the skin tissue, with the exception of amino acids and their derivatives ,.
  • a substance to be recognized as a chlorine or potassium channel receptor agonist it must have at least one of the following characteristics:
  • taurine As agonist substances which can be used in the invention to activate the sensitive glycine-strychnine receptors associated with the chlorine channels, mention may be made of taurine.
  • GABA gamma-aminobutyric acid
  • isoguvacin isonipecotic acid
  • isonipecotic acid 4,5,6,7-tetrahydroisoxazolo- (5,4-c) pyridin-3 (2H) -one
  • benzodiazepines such as nitrazepam (1, 3-dihydro-7-nitro-5-phenyl-2H-1, 4-benzodiazepin-2-one), diazepam (7-chloro-1, 3-dihydro-1-methyl -5-phenyl-2H-1, 4-benzodiazepin-2-one), flunitrazepam (5- (2-fluoro-phenyl) -1, 3-dihydro-1-methyl-7-nitro-2H-1, 4 -benzo-diazepin-2-one) and oxazepam (7-chloro-1, 3-dihydro-3-
  • Minoxidil As agonist substance of receptors associated with potassium channels, which can be used in the invention, mention may be made of Minoxidil, pinacidil, nicorandil, cromokakim.
  • the agonist of a receptor associated with the chlorine or potassium channel is preferably used in an amount ranging from 0.00001 to 20% by weight relative to the total weight of the composition, and in particular in an amount ranging from 0.001 to 10% by weight relative to the total weight of the composition.
  • compositions according to the invention can be presented in all the galenical forms normally used for a topical application.
  • compositions according to the invention are those conventionally used in the fields under consideration and are appropriate to their galenical form.
  • compositions for topical application of the invention comprise a medium compatible with the skin, including the scalp, the mucous membranes such as the lips.
  • These compositions may be in particular in the form of aqueous, alcoholic or hydroalcoholic solutions, gels, water-in-oil or oil-in-water emulsions having the appearance of a cream or a gel, of micro- emulsions, aerosols, or even in the form of vesicular dispersions containing ionic and / or nonionic lipids.
  • These dosage forms are prepared according to the usual methods of the fields considered.
  • compositions for topical application may especially constitute a cosmetic, dermatological protection, treatment or care composition for the face, the neck, the hands or the body, (for example a day cream, night cream, sun cream or oil. , body milk), a makeup composition (for example a foundation) or an artificial tanning composition.
  • the proportion of fatty substances that it contains can range from 5% to 80% by weight, and preferably from 5% to 50% by weight relative to the total weight of the composition .
  • the fatty substances and the emulsifiers used in the composition in the form of an emulsion are chosen from those conventionally used in the cosmetic or dermatological field.
  • oils of mineral origin (petrolatum), oils of vegetable origin (liquid fraction of shea butter) and their hydrogenated derivatives, oils of animal origin, oils of synthesis (perhydrosqualene), silicone oils (dimethylpolysiloxane) and fluorinated oils.
  • oils of mineral origin petrolatum
  • oils of vegetable origin liquid fraction of shea butter
  • oils of synthesis perhydrosqualene
  • silicone oils dimethylpolysiloxane
  • fluorinated oils fatty substances which can be used in the invention
  • fatty alcohols cetyl alcohol, stearyl alcohol
  • fatty acids stearic acid
  • the emulsifiers may be present in the composition in a proportion ranging from 0.3% to 30% by weight, and preferably from 0.5 to 30% by weight relative to the total weight of the composition.
  • the cosmetic or dermatological compositions of the invention may also contain adjuvants customary in the corresponding fields, such as hydrophilic or lipophilic gelling agents, preservatives, antioxidants, solvents, perfumes, fillers, filters and coloring matters.
  • these compositions can contain hydrophilic or lipophilic active agents.
  • the amounts of these various adjuvants or active agents are those conventionally used in the cosmetic or dermatological field, and for example from 0.01% to 20% of the total weight of the composition.
  • These adjuvants or these active agents depending on their nature, can be introduced into the fatty phase, into the aqueous phase and / or into lipid vesicles.
  • the lotion obtained acts on sensitive skin during repeated use (twice-daily application for one month).
  • the gel obtained can be applied daily morning and evening for a month.
  • Triethanolamine neutralizer 0.7 0 // o
  • Carbomer (Carbopol 940 sold by the company Goodrich) 0.4 / o

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention concerns the use of one or several substances agonists of one or several receptors associated with a chlorine canal or a potassium canal in a cosmetic and/or dermatological composition, for treating sensitive skins and more particularly for eliminating itching, pruritus, stabbing pains, tingling and/or erythema. The agonist substance is in particular taurine, gamma-aminobutyric (GABA), isoguvacin, isonipecotic acid, 4,5,6,7-tetrahydroisoazolo-(5,4-c)pyridin-3(2H)-one, benzodiazepines, steroids, cromakalim, pinacidil, nicorandil and minoxidil.

Description

Utilisation d'une substance agoniste d'un récepteur associé à un canal chlore ou potassique dans le traitement des peaux sensibles Use of a receptor agonist substance associated with a chlorine or potassium channel in the treatment of sensitive skin
La présente invention se rapporte à l'utilisation d'une substance agoniste d'un récepteur associé à un canal chlore ou à un canal potassium, à l'exception des acides aminés et de leurs dérivés, dans une composition cosmétique et/ou dermatologique, en vue de traiter les peaux sensibles, y compris le cuir chevelu, et les muqueuses, d'êtres humains. Elle se rapporte aussi à un procédé de traitement des peaux sensibles.The present invention relates to the use of an agonist substance of a receptor associated with a chlorine channel or with a potassium channel, with the exception of amino acids and their derivatives, in a cosmetic and / or dermatological composition, to treat sensitive skin, including the scalp, and mucous membranes, of humans. It also relates to a method of treating sensitive skin.
II est connu que certaines peaux sont plus sensibles que d'autres. Les symptômes des peaux sensibles étaient jusqu'à présent mal caractérisés et le problème de ces peaux était, de ce fait, mal défini ; personne ne connaissait exactement le processus mis en cause dans la sensibilité de la peau. Certains pensaient qu'une peau sensible était une peau qui réagissait aux produits cosmétiques, d'autres qu'il s'agissait d'une peau qui réagissait à plusieurs facteurs extérieurs, pas forcément liés aux produits cosmétiques. Certains tests ont été mis au point pour tenter de cerner les peaux sensibles, par exemple des tests à l'acide lactique et au DMSO qui sont connus pour être des substances irritantes : voir par exemple l'article de K. Lammintausta et al., Dermatoses, 1988, 36, pages 45-49, et l'article de T. Agner et J. Serup, Clinical and Expérimental Dermatology, 1989, 14, pages 214-217. Malheureusement, ces tests ne permettent pas de caractériser correctement les peaux sensibles. Par ailleurs, on assimilait les peaux sensibles à des peaux allergiques. Du fait que l'on connaissait mal les caractéristiques des peaux sensibles, il était jusqu'à présent très difficile de les traiter, et on les traitait indirectement, par exemple en limitant dans les compositions cosmétiques l'emploi de produits à caractère irritant tels que les tensioactifs, les conservateurs ou les parfums.It is known that certain skins are more sensitive than others. The symptoms of sensitive skin have so far been poorly characterized and the problem of this skin has therefore been ill defined; no one knew exactly the process involved in the sensitivity of the skin. Some thought that sensitive skin was skin that reacted to cosmetic products, others that it was skin that reacted to several external factors, not necessarily linked to cosmetic products. Certain tests have been developed to try to identify sensitive skin, for example tests with lactic acid and with DMSO which are known to be irritating substances: see for example the article by K. Lammintausta et al., Dermatoses, 1988, 36, pages 45-49, and the article by T. Agner and J. Serup, Clinical and Experimental Dermatology, 1989, 14, pages 214-217. Unfortunately, these tests do not correctly characterize sensitive skin. In addition, sensitive skin was assimilated to allergic skin. Due to the fact that little was known about the characteristics of sensitive skin, it has hitherto been very difficult to treat them, and they have been treated indirectly, for example by limiting in cosmetic compositions the use of products with an irritant nature such as surfactants, preservatives or perfumes.
La demanderesse a réalisé de nombreux tests cliniques et a su déterminer les symptômes liés aux peaux sensibles. Ces symptômes sont en particulier des signes subjectifs, qui sont essentiellement des sensations dysesthésiques. On entend par sensations dysesthésiques des sensations plus ou moins douloureuses ressenties dans une zone cutanée comme les picotements, fourmillements, démangeaisons ou prurits, brûlures, échauffements, inconforts, tiraillements, etc. La demanderesse a pu notamment montrer qu'une peau sensible n'était pas une peau allergique. (Voir à cet effet le brevet FR-A-2 719 474). La demanderesse a ainsi trouvé que les peaux sensibles pouvaient être scindées en deux grandes formes cliniques, les peaux irritables et/ou réactives, et les peaux intolérantes.The Applicant has carried out numerous clinical tests and has been able to determine the symptoms associated with sensitive skin. These symptoms are in particular subjective signs, which are essentially dysaesthetic sensations. By dysesthetic sensations is meant more or less painful sensations felt in a skin area such as tingling, tingling, itching or itching, burning, heating, discomfort, tightness, etc. The Applicant has in particular been able to show that sensitive skin is not allergic skin. (See for this purpose patent FR-A-2,719,474). The Applicant has thus found that sensitive skin can be divided into two main clinical forms, irritable and / or reactive skin, and intolerant skin.
Une peau irritable et/ou réactive est une peau qui réagit par un prurit, c'est-à-dire par des démangeaisons, ou par des picotements, à différents facteurs tels que l'environnement, les émotions, les aliments, le vent, les frottements, le rasoir, le savon, les tensioactifs, l'eau dure à forte concentration de calcaire, les variations de température ou la laine. En général, ces signes sont associés à une peau sèche avec ou sans dartres, ou à une peau qui présente un érythème. Une peau intolérante est une peau qui réagit par des sensations d'échauffement, de tiraillements, de fourmillements et/ou de rougeurs, à différents facteurs tels que l'environnement, les émotions, les aliments. En général, ces signes sont associés à une peau hyperséborrhéique ou acnéique avec ou sans dartres, et à un érythème.Irritable and / or reactive skin is skin that reacts with pruritus, that is to say, by itching, or by tingling, to various factors such as the environment, emotions, food, wind, friction, razor, soap, surfactants, hard water with a high concentration of lime, temperature variations or wool. In general, these signs are associated with dry skin with or without sores, or with skin that has an erythema. Intolerant skin is skin that reacts with feelings of heating, tightness, tingling and / or redness, to various factors such as the environment, emotions, food. In general, these signs are associated with hyperseborrheic or acne-prone skin with or without sores, and erythema.
Les cuirs chevelus "sensibles" ont une sémiologie clinique plus univoque : les sensations de prurit et/ou de picotements et/ou d'échauffements sont essentiellement déclenchés par des facteurs locaux tels que frottements, savon, tensioactifs, eau dure à forte concentration de calcaire, shampooings ou lotions. Ces sensations sont aussi parfois déclenchées par des facteurs tels que l'environnement, les émotions et/ou les aliments. Un érythème et une hyperséborrhée du cuir chevelu ainsi qu'un état pelliculaire sont fréquemment associés aux signes précédents."Sensitive" scalps have a more unequivocal clinical semiology: the sensations of pruritus and / or tingling and / or overheating are essentially triggered by local factors such as friction, soap, surfactants, hard water with a high concentration of limestone. , shampoos or lotions. These sensations are also sometimes triggered by factors such as the environment, emotions and / or food. Erythema and hyperseborrhea of the scalp and dandruff are frequently associated with the above signs.
Par ailleurs, dans certaines régions anatomiques comme les grands plis (régions inguinales, génitale, axillaires, poplitées, anale, sous-mammaires, plis du coude) et les pieds, la peau sensible se traduit par des sensations prurigineuses et/ou des sensations dysesthésiques (échauffement, picotements) liées en particulier à la sueur, aux frottements, à la laine, aux tensioactifs, à l'eau dure à forte concentration en calcaire et/ou aux variations de température.In addition, in certain anatomical regions such as the large folds (inguinal, genital, axillary, popliteal, anal, submammary, elbow folds) and the feet, sensitive skin results in itchy sensations and / or dysesthetic sensations. (heating, tingling) related in particular to sweat, friction, wool, surfactants, hard water with a high lime concentration and / or temperature variations.
Pour déterminer si une peau est sensible ou non, la demanderesse a également mis au point des tests notamment à la capsaïcine et à la triéthanolamine.To determine whether a skin is sensitive or not, the applicant has also developed tests in particular with capsaicin and triethanolamine.
La demanderesse a maintenant découvert que les peaux sensibles était liée à une modification de l'excitabilité nerveuse cutanée. Par conséquent, l'utilisation d'agonistes des récepteurs associés aux canaux chlore et/ou potassique présents dans le tissu cutané peut permettre d'obtenir un effet préventif et/ou curatif des peaux sensibles.The Applicant has now discovered that sensitive skin is linked to a change in the nervous excitability of the skin. Therefore, the use receptor agonists associated with the chlorine and / or potassium channels present in the skin tissue can make it possible to obtain a preventive and / or curative effect for sensitive skin.
En effet, les membranes cellulaires de chaque fibre nerveuse comportent de nombreux canaux ioniques, et notamment des canaux chlore ou potassique. Le rôle de ces différents canaux est de permettre aux ions chlorures et potassium, un passage de part et d'autre de la membrane cellulaire nerveuse, ces échanges ioniques (entrées de chlorures chargés négativement et sorties de potassium chargé positivement) conduisent à des modifications électriques qui rendent les fibres nerveuses sensitives moins excitables (ce phénomène est appelé hyperpolarisation membranaire). Les récepteurs neuronaux associés aux canaux chlore ou potassique sont notamment pour les canaux chlore des récepteurs pour la glycine (les récepteurs glycine-strychnine sensibles) et des récepteurs pour le GABA (les récepteurs GABAA).In fact, the cell membranes of each nerve fiber include numerous ion channels, and in particular chlorine or potassium channels. The role of these different channels is to allow the chlorides and potassium ions, a passage on both sides of the nervous cell membrane, these ionic exchanges (negatively charged chloride inlets and positively charged potassium exits) lead to electrical modifications. which make sensitive nerve fibers less excitable (this phenomenon is called membrane hyperpolarization). The neural receptors associated with the chlorine or potassium channels are in particular for the chlorine channels receptors for glycine (sensitive glycine-strychnine receptors) and receptors for GABA (GABAA receptors).
Par ailleurs, on sait que dans le système nerveux central, il est possible de diminuer l'excitabilité cellulaire par divers agents pharmacologiques agissant sur les récepteurs glycine-strychnine sensibles ou sur les récepteurs GABAA associés au canaux chlore du système nerveux central (voir W. Sieghart, Trends in Pharmacological Science, décembre 1992, vol. 131 , pages 446 à 450). D'autre part, il est également possible de diminuer l'excitabilité cellulaire par différents agents pharmacologiques agissant sur les canaux potassiques (voir S.D. Longman, Médicinal Research Reviews, 1992, vol. 12, page 73).Furthermore, it is known that in the central nervous system, it is possible to reduce cellular excitability by various pharmacological agents acting on the sensitive glycine-strychnine receptors or on the GABAA receptors associated with the chlorine channels of the central nervous system (see W. Sieghart, Trends in Pharmacological Science, December 1992, vol. 131, pages 446-450). On the other hand, it is also possible to decrease cell excitability by various pharmacological agents acting on potassium channels (see S.D. Longman, Medicinal Research Reviews, 1992, vol. 12, page 73).
La demanderesse a trouvé que le tissu cutané comportait des récepteurs associés aux canaux chlore ou potassique, ce qui, jusqu'à présent, n'avait pas été envisagé et qu'il existait un lien entre les canaux chlore ou potassique des fibres nerveuses sensitives du système nerveux périphérique cutané et les peaux sensibles. Elle a donc trouvé que l'on pouvait agir sur ces canaux pour traiter les peaux sensibles.The Applicant has found that the skin tissue contains receptors associated with the chlorine or potassium channels, which, until now, had not been envisaged and that there was a link between the chlorine or potassium channels of the sensitive nerve fibers of the peripheral nervous system of the skin and sensitive skin. She therefore found that we could act on these channels to treat sensitive skin.
Personne n'avait, jusqu'à ce jour, établi un lien entre les canaux chlore ou potassique des fibres nerveuses sensitives du système nerveux périphérique cutané et les peaux sensibles, et n'avait trouvé que l'on pouvait traiter les peaux sensibles en agissant sur les canaux chlore ou potassique par activation des récepteurs se trouvant dans ou au voisinage de ces canaux. Les substances qui peuvent activer les récepteurs des canaux chlore ou potassique, et donc entraîner l'entrée d'ions chlorure ou potassium dans les cellules, sont appelées substances agonistes.No one had, to date, established a link between the chlorine or potassium channels of the sensitive nerve fibers of the cutaneous peripheral nervous system and sensitive skin, and had not found that sensitive skin can be treated by acting on the chlorine or potassium channels by activation of the receptors located in or in the vicinity of these channels. Substances that can activate the chlorine or potassium channel receptors, and therefore cause the entry of chloride or potassium ions into cells, are called agonist substances.
Aussi, la présente invention se rapporte à l'utilisation d'au moins une substance agoniste d'au moins un récepteur associé à au moins un canal chlore ou potassique, présent dans le tissu cutané, à l'exception des acides aminés et de leurs dérivés, dans et/ou pour la fabrication d'une composition cosmétique ou dermatologique topique pour traiter les peaux sensibles.Also, the present invention relates to the use of at least one agonist substance of at least one receptor associated with at least one chlorine or potassium channel, present in the skin tissue, with the exception of amino acids and their derivatives, in and / or for the manufacture of a topical cosmetic or dermatological composition for treating sensitive skin.
L'invention a également pour objet l'utilisation d'au moins une substance agoniste d'au moins un récepteur associé à au moins un canal chlore ou potassique, présent dans le tissu cutané, à l'exception des acides aminés et de leurs dérivés, dans et/ou pour la fabrication d'une composition cosmétique ou dermatologique topique pour traiter, voire supprimer, les démangeaisons, les prurits, les fourmillements, les échauffements, les tiraillements, les picotements et/ou les érythèmes.The invention also relates to the use of at least one agonist substance of at least one receptor associated with at least one chlorine or potassium channel, present in the skin tissue, with the exception of amino acids and their derivatives. , in and / or for the manufacture of a topical cosmetic or dermatological composition for treating, or even eliminating, itching, pruritus, tingling, heating, tightness, tingling and / or erythema.
L'invention se rapporte encore à l'utilisation d'au moins une substance agoniste d'au moins un récepteur associé à au moins un canal chlore ou potassique d'au moins une afférence nerveuse cutanée, à l'exception des acides aminés et de leurs dérivés, dans et/ou pour la fabrication d'une composition cosmétique ou dermatologique topique pour traiter les peaux sensibles.The invention also relates to the use of at least one agonist substance of at least one receptor associated with at least one chlorine or potassium channel of at least one cutaneous nerve afference, with the exception of amino acids and their derivatives, in and / or for the manufacture of a topical cosmetic or dermatological composition for treating sensitive skin.
L'invention se rapporte encore à l'utilisation d'au moins une substance agoniste d'au moins un récepteur associé à au moins un canal chlore ou potassique d'au moins une afférence nerveuse cutanée, à l'exception des acides aminés et de leurs dérivés, dans et/ou pour la fabrication d'une composition cosmétique et/ou dermatologique topique pour traiter, voire supprimer, les démangeaisons, les prurits, les fourmillements, les échauffements, les tiraillements, les picotements et/ou les érythèmes.The invention also relates to the use of at least one agonist substance of at least one receptor associated with at least one chlorine or potassium channel of at least one cutaneous nerve afference, with the exception of amino acids and their derivatives, in and / or for the manufacture of a topical cosmetic and / or dermatological composition for treating, or even eliminating, itching, pruritus, tingling, overheating, tightness, tingling and / or erythema.
L'invention a aussi pour objet un procédé de traitement cosmétique des peaux sensibles, consistant à appliquer topiquement sur la peau d'un sujet à peau sensible, une composition topique cosmétique, contenant au moins une substance agoniste d'au moins un récepteur associé à au moins un canal chlore ou potassique présent dans le tissu cutané, à l'exception des acides aminés et de leurs dérivés,. Il existe plusieurs récepteurs associés au canal chlore ou potassique. Il s'agit notamment des récepteurs glycine-strychnine sensibles et des récepteurs GABAA, ces derniers comportant eux-mêmes plusieurs sous-unités constituées par le site GABA, le site benzodiazépine et un site de type stéroïde. Toutes les substances agissant comme agonistes de ces récepteurs ou sites peuvent être utilisées pour traiter les peaux sensibles conformément à l'invention.The subject of the invention is also a method of cosmetic treatment of sensitive skin, consisting in applying topically to the skin of a subject with sensitive skin, a cosmetic topical composition, containing at least one agonist substance of at least one receptor associated with at least one chlorine or potassium channel present in the skin tissue, with the exception of amino acids and their derivatives ,. There are several receptors associated with the chlorine or potassium channel. These include sensitive glycine-strychnine receptors and GABAA receptors, the latter themselves comprising several subunits constituted by the GABA site, the benzodiazepine site and a steroid type site. All the substances acting as agonists of these receptors or sites can be used to treat sensitive skin in accordance with the invention.
Pour qu'une substance soit reconnue comme un agoniste des récepteurs des canaux chlore ou potassique, elle doit répondre à l'une au moins des caractéristiques suivantes :For a substance to be recognized as a chlorine or potassium channel receptor agonist, it must have at least one of the following characteristics:
- montrer un effet myorelaxant dans un test fonctionnel sur organe isolé ; et/ou- show a muscle relaxant effect in a functional test on an isolated organ; and or
- montrer une activité de type ouvreur de canaux chlore ou potassique par mesure électrophysiologique, éventuellement par le biais d'une fixation à au moins un des différents récepteurs associés au canal chlore ou potassique.- show an activity of the chlorine or potassium channel opener type by electrophysiological measurement, possibly by fixing to at least one of the different receptors associated with the chlorine or potassium channel.
Comme substances agonistes utilisables dans l'invention pour activer les récepteurs à la glycine-strychnine sensibles associés au canaux chlore, on peut citer la taurine.As agonist substances which can be used in the invention to activate the sensitive glycine-strychnine receptors associated with the chlorine channels, mention may be made of taurine.
Comme substances agonistes utilisables dans l'invention pour activer les récepteurs au GABAA associés aux canaux chlore, on peut citer l'acide gamma- aminobutyrique (GABA) ; l'isoguvacine ; l'acide isonipécotique ; la 4,5,6,7- tétrahydroisoxazolo-(5,4-c)pyridin-3(2H)-one (THIP) ; les benzodiazepines telles que le nitrazépam (1 ,3-dihydro-7-nitro-5-phényl-2H-1 ,4-benzodiazépin-2-one), le diazépam (7-chloro-1 ,3-dihydro-1-méthyl-5-phényl-2H-1 ,4-benzodiazépin-2-one), le flunitrazépam (5-(2-fluoro-phényl)-1 ,3-dihydro-1-méthyl-7-nitro-2H-1 ,4-benzo- diazépin-2-one) et l'oxazépam (7-chloro-1 ,3-dihydro-3-hydroxy-5-phényl-2H-1 ,4- benzodiazépin-2-one) ; certains stéroïdes tels que l'alfaxalone (3-hydroxy- prégnane-11 ,20-dione).As agonist substances which can be used in the invention to activate the GABAA receptors associated with the chlorine channels, mention may be made of gamma-aminobutyric acid (GABA); isoguvacin; isonipecotic acid; 4,5,6,7-tetrahydroisoxazolo- (5,4-c) pyridin-3 (2H) -one (THIP); benzodiazepines such as nitrazepam (1, 3-dihydro-7-nitro-5-phenyl-2H-1, 4-benzodiazepin-2-one), diazepam (7-chloro-1, 3-dihydro-1-methyl -5-phenyl-2H-1, 4-benzodiazepin-2-one), flunitrazepam (5- (2-fluoro-phenyl) -1, 3-dihydro-1-methyl-7-nitro-2H-1, 4 -benzo-diazepin-2-one) and oxazepam (7-chloro-1, 3-dihydro-3-hydroxy-5-phenyl-2H-1, 4-benzodiazepin-2-one); certain steroids such as alfaxalone (3-hydroxy-pregnane-11, 20-dione).
Comme substance agoniste des récepteurs associés aux canaux potassiques, utilisables dans l'invention, on peut citer le Minoxidil, le pinacidil, le nicorandil, le cromokakim.As agonist substance of receptors associated with potassium channels, which can be used in the invention, mention may be made of Minoxidil, pinacidil, nicorandil, cromokakim.
Dans les compositions selon l'invention, l'agoniste d'un récepteur associé au canal chlore ou potassique est utilisé de préférence en une quantité allant de 0,00001 à 20 % en poids par rapport au poids total de la composition, et en particulier en une quantité allant de 0,001 à 10 % en poids par rapport au poids total de la composition.In the compositions according to the invention, the agonist of a receptor associated with the chlorine or potassium channel is preferably used in an amount ranging from 0.00001 to 20% by weight relative to the total weight of the composition, and in particular in an amount ranging from 0.001 to 10% by weight relative to the total weight of the composition.
Les compositions selon l'invention peuvent se présenter sous toutes les formes galéniques normalement utilisées pour une application topique.The compositions according to the invention can be presented in all the galenical forms normally used for a topical application.
Les quantités des différents constituants des compositions selon l'invention sont celles classiquement utilisées dans les domaines considérés et sont appropriées à leur forme galénique.The amounts of the various constituents of the compositions according to the invention are those conventionally used in the fields under consideration and are appropriate to their galenical form.
Les compositions à application topique de l'invention comprennent un milieu compatible avec la peau, y compris le cuir chevelu, les muqueuses comme les lèvres. Ces compositions peuvent se présenter notamment sous forme de solutions aqueuses, alcooliques ou hydroalcooliques, de gels, d'émulsions eau- dans-huile ou huile-dans-eau ayant l'aspect d'une crème ou d'un gel, de micro- émulsions, d'aérosols, ou encore sous forme de dispersions vésiculaires contenant des lipides ioniques et/ou non ioniques. Ces formes galéniques sont préparées selon les méthodes usuelles des domaines considérés.The compositions for topical application of the invention comprise a medium compatible with the skin, including the scalp, the mucous membranes such as the lips. These compositions may be in particular in the form of aqueous, alcoholic or hydroalcoholic solutions, gels, water-in-oil or oil-in-water emulsions having the appearance of a cream or a gel, of micro- emulsions, aerosols, or even in the form of vesicular dispersions containing ionic and / or nonionic lipids. These dosage forms are prepared according to the usual methods of the fields considered.
Ces compositions à application topique peuvent constituer notamment une composition de protection, de traitement ou de soin cosmétique ou dermatologique pour le visage, le cou, les mains ou le corps, (par exemple une crème de jour, crème de nuit, crème ou huile solaire, un lait corporel), une composition de maquillage (par exemple un fond de teint) ou une composition de bronzage artificiel.These compositions for topical application may especially constitute a cosmetic, dermatological protection, treatment or care composition for the face, the neck, the hands or the body, (for example a day cream, night cream, sun cream or oil. , body milk), a makeup composition (for example a foundation) or an artificial tanning composition.
Quand la composition de l'invention est une émuision, la proportion de corps gras qu'elle contient peut aller de 5 % à 80 % en poids, et de préférence de 5 % à 50 % en poids par rapport au poids total de la composition. Les corps gras et les émulsionnants utilisés dans la composition sous forme d'émulsion sont choisis parmi ceux classiquement utilisés dans le domaine cosmétique ou dermatologique.When the composition of the invention is an emulsion, the proportion of fatty substances that it contains can range from 5% to 80% by weight, and preferably from 5% to 50% by weight relative to the total weight of the composition . The fatty substances and the emulsifiers used in the composition in the form of an emulsion are chosen from those conventionally used in the cosmetic or dermatological field.
Comme corps gras utilisables dans l'invention, on peut citer les huiles d'origine minérale (vaseline), les huiles d'origine végétale (fraction liquide de beurre de karité) et leurs dérivés hydrogénés, les huiles d'origine animale, les huiles de synthèse (perhydrosqualène), les huiles siliconées (diméthylpolysiloxane) et les huiles fluorées. Comme autres corps gras, on peut encore citer les alcools gras (alcool cétylique, alcool stéarylique), les acides gras (acide stéarique) et les cires.As fatty substances which can be used in the invention, mention may be made of oils of mineral origin (petrolatum), oils of vegetable origin (liquid fraction of shea butter) and their hydrogenated derivatives, oils of animal origin, oils of synthesis (perhydrosqualene), silicone oils (dimethylpolysiloxane) and fluorinated oils. As other fatty substances, mention may also be made of fatty alcohols (cetyl alcohol, stearyl alcohol), fatty acids (stearic acid) and waxes.
Les émulsionnants peuvent être présents, dans la composition, en une proportion allant de 0,3 % à 30 % en poids, et de préférence de 0,5 à 30 % en poids par rapport au poids total de la composition.The emulsifiers may be present in the composition in a proportion ranging from 0.3% to 30% by weight, and preferably from 0.5 to 30% by weight relative to the total weight of the composition.
De façon connue, les compositions cosmétiques ou dermatologiques de l'invention peuvent contenir également des adjuvants habituels dans les domaines correspondants, tels que les gélifiants hydrophiles ou lipophiles, les conservateurs, les antioxydants, les solvants, les parfums, les charges, les filtres et les matières colorantes. Par ailleurs, ces compositions peuvent contenir des actifs hydrophiles ou lipophiles. Les quantités de ces différents adjuvants ou actifs sont celles classiquement utilisées dans le domaine cosmétique ou dermatologique, et par exemple de 0,01 % à 20 % du poids total de la composition. Ces adjuvants ou ces actifs, selon leur nature, peuvent être introduits dans la phase grasse, dans la phase aqueuse et/ou dans des vésicules lipidiques.In a known manner, the cosmetic or dermatological compositions of the invention may also contain adjuvants customary in the corresponding fields, such as hydrophilic or lipophilic gelling agents, preservatives, antioxidants, solvents, perfumes, fillers, filters and coloring matters. Furthermore, these compositions can contain hydrophilic or lipophilic active agents. The amounts of these various adjuvants or active agents are those conventionally used in the cosmetic or dermatological field, and for example from 0.01% to 20% of the total weight of the composition. These adjuvants or these active agents, depending on their nature, can be introduced into the fatty phase, into the aqueous phase and / or into lipid vesicles.
Les exemples qui suivent sont donnés à titre illustratif afin de mieux faire comprendre l'invention. Les quantités indiquées sont des pourcentages en poids.The following examples are given by way of illustration in order to better understand the invention. The quantities indicated are percentages by weight.
EXEMPLE 1 : Lotion de soin pour le visageEXAMPLE 1 Care Lotion for the Face
Taurine 8 %Taurine 8%
Antioxydant 0,05 %Antioxidant 0.05%
Conservateur 0,3 %Preservative 0.3%
Ethanol (solvant) 8 % Eau qsp 100 %Ethanol (solvent) 8% Water qs 100%
La lotion obtenue agit sur les peaux sensibles lors d'une utilisation répétée (application bi-quotidienne pendant un mois).The lotion obtained acts on sensitive skin during repeated use (twice-daily application for one month).
EXEMPLE 2 : Gel pour le soin du visageEXAMPLE 2 Gel for Facial Care
Minoxidil 0,5 % Hydroxypropylcellulose (Klucel H vendu par la sociétéMinoxidil 0.5% Hydroxypropylcellulose (Klucel H sold by the company
Hercules) (gélifiant) 1 %Hercules) (gelling agent) 1%
Conservateur 0,3 %Preservative 0.3%
Ethanol (solvant) 15 %Ethanol (solvent) 15%
Antioxydant 0,05 %Antioxidant 0.05%
Eau qsp 100 %Water qs 100%
Le gel obtenu peut être appliqué quotidiennement matin et soir pendant un mois.The gel obtained can be applied daily morning and evening for a month.
EXEMPLE 3 : Crème de soin du visage (emulsion huile-dans-eau)EXAMPLE 3 Face cream (oil-in-water emulsion)
Flunitrazépam 0,1 /oFlunitrazepam 0.1 / o
Stéarate de glycérol (émulsionnant) 2 0 //o Polysorbate 60 (Tween 60 vendu par la société ICI) (émulsionnant )) 1 0 //oGlycerol stearate (emulsifier) 2 0 // o Polysorbate 60 (Tween 60 sold by the company ICI) (emulsifier)) 1 0 // o
Acide stéarique 1,4 0 //oStearic acid 1.4 0 // o
Triéthanolamine (neutralisant) 0,7 0 //oTriethanolamine (neutralizer) 0.7 0 // o
Carbomer (Carbopol 940 vendu par la société Goodrich) 0,4 /oCarbomer (Carbopol 940 sold by the company Goodrich) 0.4 / o
Fraction liquide de beurre de karité 12 0 //o Perhydrosqualène 12 0 //oLiquid fraction of shea butter 12 0 // o Perhydrosqualene 12 0 // o
Conservateur 0,3 0 //oPreservative 0.3 0 // o
Parfum 0,5 /oPerfume 0.5 / o
Antioxydant 0,05 0 //oAntioxidant 0.05 0 // o
Eau qsp 100 ° //oWater qs 100 ° // o
On obtient une crème blanche, onctueuse, qui agit sur les peaux sensibles, et que l'on peut appliquer quotidiennement.We obtain a white, creamy cream, which acts on sensitive skin, and which we can apply daily.
EXEMPLE 4 : Crème de soin du visage (emulsion huile-dans-eau)EXAMPLE 4 Face cream (oil-in-water emulsion)
Flunitrazépam 0,2 %0.2% Flunitrazepam
Mono-, distéarate de glycérol 2 % Alcool cétyiique 1,5 % Mélange alcool cétylstéarylique/alcool cétyistéarylique oxy- éthyléné 33 OE 7 % Diméthyipolysiloxane 1,5 % Huile de vaseline 17,5 % 0,3 %Mono-, glycerol distearate 2% Cetyl alcohol 1.5% Cetylstearyl alcohol / oxyethylenated cetyl alcohol 33 OE 7% Dimethyipolysiloxane 1.5% Vaseline oil 17.5% 0.3%
Conservateur % Preservative %
Parfum 12 5 0/o Perfume 12 5 0 / o
G|ycérine qsp 100 % G | y cerine qs 100%
Eau Water

Claims

REVENDICATIONS
1. Utilisation d'au moins une substance agoniste d'au moins un récepteur associé à au moins un canal chlore ou potassique présent dans le tissu cutané, à l'exception des acides aminés et de leurs dérivés, dans et/ou pour la fabrication d'une composition cosmétique ou dermatologique topique pour traiter les peaux sensibles.1. Use of at least one agonist substance of at least one receptor associated with at least one chlorine or potassium channel present in the skin tissue, with the exception of amino acids and their derivatives, in and / or for the manufacture of a topical cosmetic or dermatological composition for treating sensitive skin.
2. Utilisation d'au moins une substance agoniste d'au moins un récepteur associé à au moins un canal chlore ou potassique d'au moins une afférence nerveuse cutanée, à l'exception des acides aminés et de leurs dérivés, dans et/ou pour la fabrication d'une composition cosmétique et/ou dermatologique topique pour traiter les peaux sensibles.2. Use of at least one agonist substance of at least one receptor associated with at least one chlorine or potassium channel of at least one cutaneous nerve afference, with the exception of amino acids and their derivatives, in and / or for the manufacture of a topical cosmetic and / or dermatological composition for treating sensitive skin.
3. Utilisation d'au moins une substance agoniste d'au moins un récepteur associé à au moins un canal chlore ou potassique présent dans le tissu cutané, à l'exception des acides aminés et de leurs dérivés, dans et/ou pour la fabrication d'une composition topique cosmétique ou dermatologique pour traiter les démangeaisons, les prurits, les fourmillements, les échauffements, les tiraillements, les picotements et/ou les érythèmes.3. Use of at least one agonist substance of at least one receptor associated with at least one chlorine or potassium channel present in the skin tissue, with the exception of amino acids and their derivatives, in and / or for the manufacture of a cosmetic or dermatological topical composition for treating itching, pruritus, tingling, heating, tightness, tingling and / or erythema.
4. Utilisation d'au moins une substance agoniste d'au moins un récepteur associé à au moins un canal chlore ou potassique d'au moins une afférence nerveuse cutanée, à l'exception des acides aminés et de leurs dérivés, dans et/ou pour la fabrication d'une composition cosmétique ou dermatologique topique pour traiter les démangeaisons, les prurits, les fourmillements, les échauffements, les tiraillements, les picotements et/ou les érythèmes.4. Use of at least one agonist substance of at least one receptor associated with at least one chlorine or potassium channel of at least one skin nerve afference, with the exception of amino acids and their derivatives, in and / or for the manufacture of a topical cosmetic or dermatological composition for treating itching, pruritus, tingling, overheating, tightness, tingling and / or erythema.
5. Utilisation selon l'une des revendications 1 à 4, caractérisée en ce que la substance agoniste est choisie dans le groupe comprenant la taurine, l'acide gamma-aminobutyrique, l'isoguvacine, l'acide isonipécotique, la 4,5,6,7- tétrahydroisoxa-zolo-(5,4-c)pyridin-3(2H)-one, les benzodiazepines, les stéroïdes, le nicorandil, le pinacidil, le minoxidil, le cromokaiim.5. Use according to one of claims 1 to 4, characterized in that the agonist substance is chosen from the group comprising taurine, gamma-aminobutyric acid, isoguvacin, isonipecotic acid, 4,5, 6,7- tetrahydroisoxa-zolo- (5,4-c) pyridin-3 (2H) -one, benzodiazepines, steroids, nicorandil, pinacidil, minoxidil, cromokaiim.
6. Utilisation selon l'une quelconque des revendications 1 à 5, caractérisée en ce que la substance agoniste est présente dans la composition en une quantité allant de 0,00001 à 20 % en poids par rapport au poids total de la composition. 6. Use according to any one of claims 1 to 5, characterized in that the agonist substance is present in the composition in an amount ranging from 0.00001 to 20% by weight relative to the total weight of the composition.
7. Utilisation selon l'une quelconque des revendications 1 à 6, caractérisée en ce que la substance agoniste est présente dans la composition en une quantité allant de 0,001 à 10 % en poids par rapport au poids total de la composition.7. Use according to any one of claims 1 to 6, characterized in that the agonist substance is present in the composition in an amount ranging from 0.001 to 10% by weight relative to the total weight of the composition.
8. Utilisation selon l'une quelconque des revendications 1 à 7, caractérisée en ce que la composition se présente sous forme de solutions aqueuses, alcooliques ou hydroalcooiiques, de gels, d'émulsions eau-dans-huile ou huile-dans-eau ayant l'aspect d'une crème ou d'un gel, de microémulsions, d'aérosols, ou encore sous forme de dispersions vésiculaires.8. Use according to any one of claims 1 to 7, characterized in that the composition is in the form of aqueous, alcoholic or hydroalcoholic solutions, gels, water-in-oil or oil-in-water emulsions having the appearance of a cream or gel, microemulsions, aerosols, or even in the form of vesicular dispersions.
9. Procédé de traitement cosmétique des peaux sensibles, consistant à appliquer sur la peau d'un sujet à peau sensible, une composition cosmétique contenant au moins une substance agoniste d'au moins un récepteur associé à au moins un canal chlore ou potassique, présent dans le tissu cutané, à l'exception des acides aminés et de leurs dérivés. 9. A method of cosmetic treatment of sensitive skin, consisting in applying to the skin of a subject with sensitive skin, a cosmetic composition containing at least one agonist substance of at least one receptor associated with at least one chlorine or potassium channel, present in skin tissue, with the exception of amino acids and their derivatives.
EP98942793A 1997-09-01 1998-08-27 Use of a substance agonist of a receptor associated with a chlorine or potassium canal for treating sensitive skins Withdrawn EP1009379A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9710853 1997-09-01
FR9710853A FR2767692B1 (en) 1997-09-01 1997-09-01 USE OF A AGONIST SUBSTANCE OF A RECEPTOR ASSOCIATED WITH A CHLORINE OR POTASSIAL CHANNEL IN THE TREATMENT OF SENSITIVE SKIN
PCT/FR1998/001861 WO1999011238A1 (en) 1997-09-01 1998-08-27 Use of a substance agonist of a receptor associated with a chlorine or potassium canal for treating sensitive skins

Publications (1)

Publication Number Publication Date
EP1009379A1 true EP1009379A1 (en) 2000-06-21

Family

ID=9510644

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98942793A Withdrawn EP1009379A1 (en) 1997-09-01 1998-08-27 Use of a substance agonist of a receptor associated with a chlorine or potassium canal for treating sensitive skins

Country Status (6)

Country Link
US (1) US6572848B1 (en)
EP (1) EP1009379A1 (en)
JP (1) JP2001514206A (en)
CA (1) CA2302819C (en)
FR (1) FR2767692B1 (en)
WO (1) WO1999011238A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053466A1 (en) * 2001-12-13 2003-07-03 Shiseido Company, Ltd. Skin barrier function repair accelerators

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958976A (en) * 1997-09-19 1999-09-28 E-L Management Corp. Composition and method for reducing stinging in skin
AU4841700A (en) 1999-05-12 2000-11-21 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
FR2826267B1 (en) * 2001-06-26 2005-02-25 Oreal COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING AN ASSOCIATION BETWEEN AN ELASTIC INHIBITOR COMPOUND OF THE N-ACYLAMINOAMIDE FAMILY AND AT LEAST ONE MYORELATIVE AGENT
FR2879450B1 (en) * 2004-12-20 2007-02-09 Oreal ANTAGONISTS OF PERIPHERAL RECEPTORS OF BENZODIAZEPINES FOR THE TREATMENT OF DRY SKINS
WO2006067327A2 (en) * 2004-12-20 2006-06-29 L'oreal Benzodiazepine peripheral receptor antagonists for treating dry skin
WO2006097348A1 (en) * 2005-03-15 2006-09-21 L'oreal Use of agents such as nonpolymeric nitric oxide donors for making the lips full again and/or colouring the lips
FR2883170A1 (en) * 2005-03-15 2006-09-22 Oreal Cosmetic use of an agent supporting production of nitric oxide in and/or on the skin or agents supporting cutaneous microcirculation for care and/or make-up of the skin
FR2883177B1 (en) * 2005-03-15 2008-01-25 Oreal USE OF AGRNETTS SUCH AS NON-POLYMERIC DONORS OR LIBERATORS OF NITROGEN MONOXIDE FOR NATURALLY REPELLING AND / OR COLORING LIPES
FR2883171B1 (en) * 2005-03-15 2007-05-11 Oreal USE OF AGENTS SUCH AS NON-POLYMERIC DONORS OR LIBERATORS OF NITROGEN MONOXIDE TO DECREASE POCKETS AND / OR PERIOCULAR CERNES
US20110263710A1 (en) * 2010-01-25 2011-10-27 Moskowitz Michael H Transepithelial methods of using gamma aminobutyric acid compositions for pain relief
US10981951B2 (en) 2014-01-31 2021-04-20 Mayo Foundation For Medical Education And Research Therapeutics for the treatment of glaucoma
CN108697694B (en) * 2016-01-27 2022-12-09 苏黎世大学 GABA A Use of receptor modulators for the treatment of itching
EP3796907A4 (en) 2018-05-22 2021-11-03 Neurocycle Therapeutics, Inc. Gabaa positive allosteric modulator compounds for treatment of itch and/ or dermatitis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2273514A1 (en) * 1974-06-06 1976-01-02 Orlane COSMETIC PRODUCT WITH SOFTENING ACTION ON THE SKIN
JPS63150209A (en) * 1986-12-15 1988-06-22 Kanebo Ltd Skin cosmetic
IT1223321B (en) * 1987-10-23 1990-09-19 Maria Curti COSMETIC COMPOSITIONS
US4937234A (en) * 1988-08-10 1990-06-26 Fahim Mostafa S Minerals in bioavailable form
ATE146079T1 (en) * 1990-05-31 1996-12-15 Allergan Inc USE OF PLATELE ACTIVATING FACTOR ANTAGONISTS IN PRURITUS
JPH0578243A (en) * 1990-12-11 1993-03-30 Shiseido Co Ltd Antipruritic agent and antipruritic composition
WO1992013518A1 (en) * 1991-02-06 1992-08-20 Beiersdorf Ag Stable cosmetic preparations
DE4328871A1 (en) * 1993-08-27 1995-03-02 Beiersdorf Ag Means against sensitive, hyper-reactive skin conditions, atopic dermatitis, pruritus, psoriasis prurigo, photodermatoses and ichthyosis
RU2080854C1 (en) * 1994-05-30 1997-06-10 Самсонов Владимир Николаевич Agent showing regenerative activity
DE69529043T2 (en) * 1994-09-30 2003-05-08 Oreal Use of an agonist of a receptor associated with a chloride channel for the treatment of skin folds
JPH08217695A (en) * 1995-02-10 1996-08-27 Pola Chem Ind Inc Skin preparation for external use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9911238A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053466A1 (en) * 2001-12-13 2003-07-03 Shiseido Company, Ltd. Skin barrier function repair accelerators

Also Published As

Publication number Publication date
FR2767692A1 (en) 1999-03-05
WO1999011238A1 (en) 1999-03-11
CA2302819A1 (en) 1999-03-11
FR2767692B1 (en) 2000-03-03
US6572848B1 (en) 2003-06-03
CA2302819C (en) 2006-04-18
JP2001514206A (en) 2001-09-11

Similar Documents

Publication Publication Date Title
EP0680749B1 (en) Cosmetic composition comprising an antagonist of substance P
EP0723774B1 (en) Cosmetic, dermatological or pharmaceutical composition comprising an antagonist of CGRP
CA2159555C (en) Use of a chlorine canal associated agonist material for the treatment of wrinkles
EP0859591B1 (en) Use of at least one no synthase inhibitor for treating sensitive skin
CA2165521C (en) Topical composition containing a p substance antagonist
CA2234797A1 (en) Topical composition containing capsazepine
CA2182030C (en) Use of a bradykinin antagonist in a cosmetic, pharmaceutical or dermatological composition; composition thus obtained
CA2302819C (en) Use of a substance agonist of a receptor associated with a chlorine or potassium canal for treating sensitive skins
EP0904777B1 (en) Use of an inhibitor of excitatory amino acids in cosmetic or dermatological compositions for sensitive skin and composition obtained
EP0769293B1 (en) Use of at least a beta-adrenergic agonist as an antagonist of substance P
EP0764440B1 (en) Use of at least a thermal water from Vichy as substance P antagonist
FR2758263A1 (en) USE OF AN ANTAGONIST OR AN AGONIST OF SEROTONIN RESPECTIVELY OF THE RECEPTOR 5HT2 AND 5HT1D IN A COSMETIC OR DERMATOLOGICAL COMPOSITION FOR SENSITIVE SKIN AND COMPOSITION OBTAINED
FR2738486A1 (en) Cell extracts from plant of Iridaceae family
FR2719476A1 (en) Cosmetics for application to sensitive skins
FR2809006A1 (en) USE OF MANGANESE IN COMPOSITIONS FOR COMBATING SKIN VALUE
FR2732600A1 (en) Use of alkaline earth metal salt(s)
FR2732599A1 (en) Use of alkaline earth metal salt(s)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000403

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20010221

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20030107